135 related articles for article (PubMed ID: 27598683)
1. Triage of high-risk HPV positive women in cervical cancer screening.
Ebisch RM; Siebers AG; Bosgraaf RP; Massuger LF; Bekkers RL; Melchers WJ
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1073-85. PubMed ID: 27598683
[TBL] [Abstract][Full Text] [Related]
2. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
Dijkstra MG; van Niekerk D; Rijkaart DC; van Kemenade FJ; Heideman DA; Snijders PJ; Meijer CJ; Berkhof J
Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):55-63. PubMed ID: 23733907
[TBL] [Abstract][Full Text] [Related]
3. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
4. Management of high-risk HPV-positive women for detection of cervical (pre)cancer.
Luttmer R; De Strooper LM; Steenbergen RD; Berkhof J; Snijders PJ; Heideman DA; Meijer CJ
Expert Rev Mol Diagn; 2016 Sep; 16(9):961-74. PubMed ID: 27459506
[TBL] [Abstract][Full Text] [Related]
5. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting.
Kotaniemi-Talonen L; Nieminen P; Anttila A; Hakama M
Br J Cancer; 2005 Oct; 93(8):862-7. PubMed ID: 16189520
[TBL] [Abstract][Full Text] [Related]
6. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.
Allia E; Ronco G; Coccia A; Luparia P; Macrì L; Fiorito C; Maletta F; Deambrogio C; Tunesi S; De Marco L; Gillio-Tos A; Sapino A; Ghiringhello B
Cancer Cytopathol; 2015 Apr; 123(4):212-8. PubMed ID: 25534957
[TBL] [Abstract][Full Text] [Related]
7. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
8. Evidence based appropriate triage strategies for implementing high risk HPV as primary technology in cervical cancer screening.
Pimple SA; Mishra GA; Deodhar KK
Minerva Ginecol; 2020 Apr; 72(2):96-105. PubMed ID: 32403908
[TBL] [Abstract][Full Text] [Related]
9. Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.
Nishino HT; Tambouret RH; Wilbur DC
Cancer Cytopathol; 2011 Aug; 119(4):219-27. PubMed ID: 21717588
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer screening in sub-Saharan Africa: a randomized trial of VIA versus cytology for triage of HPV-positive women.
Bigoni J; Gundar M; Tebeu PM; Bongoe A; Schäfer S; Fokom-Domgue J; Catarino R; Tincho EF; Bougel S; Vassilakos P; Petignat P
Int J Cancer; 2015 Jul; 137(1):127-34. PubMed ID: 25420434
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions.
Cuzick J; Thomas Cox J; Zhang G; Einstein MH; Stoler M; Trupin S; Behrens CM
Int J Cancer; 2013 Feb; 132(4):959-66. PubMed ID: 22806936
[TBL] [Abstract][Full Text] [Related]
12. The current position and the future perspectives of cervical cancer screening.
Bosgraaf RP; Siebers AG; De Hullu JA; Massuger LF; Bulten J; Bekkers RL; Melchers WJ
Expert Rev Anticancer Ther; 2014 Jan; 14(1):75-92. PubMed ID: 24308681
[TBL] [Abstract][Full Text] [Related]
13. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer screening: on the way to a shift from cytology to full molecular screening.
Dijkstra MG; Snijders PJ; Arbyn M; Rijkaart DC; Berkhof J; Meijer CJ
Ann Oncol; 2014 May; 25(5):927-35. PubMed ID: 24445150
[TBL] [Abstract][Full Text] [Related]
15. HLA-DP is the cervical cancer susceptibility loci among women infected by high-risk human papillomavirus: potential implication for triage of human papillomavirus-positive women.
Jia M; Han J; Hang D; Jiang J; Wang M; Wei B; Dai J; Zhang K; Guo L; Qi J; Ma H; Shi J; Ren J; Hu Z; Dai M; Li N
Tumour Biol; 2016 Jun; 37(6):8019-25. PubMed ID: 26711785
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
Holt HK; Zhang L; Zhao FH; Hu SY; Zhao XL; Zhang X; Pan QJ; Zhang WH; Smith JS; Qiao YL
Int J Cancer; 2017 Feb; 140(3):544-554. PubMed ID: 27727464
[TBL] [Abstract][Full Text] [Related]
17. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of human papilloma virus-DNA test verses colposcopy as secondary cervical cancer screening test to triage screen positive women on primary screening by visual inspection with 5% acetic acid.
Pimple S; Shastri SS
Indian J Cancer; 2014; 51(2):117-23. PubMed ID: 25104191
[TBL] [Abstract][Full Text] [Related]
19. Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples.
Verlaat W; Snoek BC; Heideman DAM; Wilting SM; Snijders PJF; Novianti PW; van Splunter AP; Peeters CFW; van Trommel NE; Massuger LFAG; Bekkers RLM; Melchers WJG; van Kemenade FJ; Berkhof J; van de Wiel MA; Meijer CJLM; Steenbergen RDM
Clin Cancer Res; 2018 Jul; 24(14):3456-3464. PubMed ID: 29632006
[No Abstract] [Full Text] [Related]
20. Cervical cancer risk profiling: molecular biomarkers predicting the outcome of hrHPV infection.
Molina MA; Carosi Diatricch L; Castany Quintana M; Melchers WJ; Andralojc KM
Expert Rev Mol Diagn; 2020 Nov; 20(11):1099-1120. PubMed ID: 33044104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
